Provided herein are humanized immunodeficient mouse comprising human myeloid cells and human lymphoid cells, wherein the human lymphoid cells comprise human B cells that produce circulating immunoglobulin (Ig), for example, physiological levels of human IgG, and wherein the mouse expresses a detectable level of human FLT3L protein and does not express a detectable level of mouse FLT3 protein.
Systems and methods for generating a graph describing cross-species relationships between gene variants associated with two or more species are provided herein. The techniques include obtaining data generated by first genomic studies of a first species and second genomic studies of a second species, the data including a plurality of datasets including two or more data formats. A subset of the data is stored in a cache and then transformed into a database having a uniform data format, the database describing graph objects and connections between the graph objects. The database is built by iteratively caching and transforming subsets of the data, each transformed subset being stored in non-transient computer-readable memory. The graph is then generated using the database.
A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.
This invention relates to genetic methods for altering gene expression in a human or animal. In particular, the invention relates to increasing expression of the TTN gene in a cell or tissue in an animal or human wherein at least one allele of the gene carries a mutation that results in a truncated Titin protein product. Therapeutic treatments, pharmaceutical compositions and methods of treatment utilizing such pharmaceutical compositions are also provided.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of non-downloadable cloud-based
software for monitoring and recording the in vivo behavior
and physiology of laboratory animals, data collection, and
data analysis; providing temporary use of non-downloadable
cloud-based software for monitoring and recording animals,
data collection, and data analysis; providing temporary use
of non-downloadable cloud-based software for studying
animals, data collection, and data analysis; providing
temporary use of non-downloadable cloud-based software for
monitoring and recording animals, data collection, and data
analysis in animal husbandry; providing temporary use of
on-line non-downloadable software for monitoring and
recording the in vivo behavior and physiology of laboratory
animals, data collection, and data analysis; providing
temporary use of on-line non-downloadable software for
monitoring and recording animals, data collection, and data
analysis; providing temporary use of on-line
non-downloadable software for studying animals, data
collection, and data analysis; providing temporary use of
on-line non-downloadable software for monitoring and
recording animals, data collection, and data analysis in
animal husbandry; software as a service (SaaS) services,
namely, hosting software for use by others for monitoring
and recording the in vivo behavior and physiology of
laboratory animals, data collection, and data analysis;
software as a service (SaaS) services, namely, hosting
software for use by others for monitoring and recording
animals, data collection, and data analysis; software as a
service (SaaS) services, namely, hosting software for use by
others for studying animals, data collection, and data
analysis; software as a service (SaaS) services, namely,
hosting software for use by others for monitoring and
recording animals, data collection, and data analysis in
animal husbandry.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of non-downloadable cloud-based
software for monitoring and recording the in vivo behavior
and physiology of laboratory animals, data collection, and
data analysis; providing temporary use of non-downloadable
cloud-based software for monitoring and recording animals,
data collection, and data analysis; providing temporary use
of non-downloadable cloud-based software for studying
animals, data collection, and data analysis; providing
temporary use of non-downloadable cloud-based software for
monitoring and recording animals, data collection, and data
analysis in animal husbandry; providing temporary use of
on-line non-downloadable software for monitoring and
recording the in vivo behavior and physiology of laboratory
animals, data collection, and data analysis; providing
temporary use of on-line non-downloadable software for
monitoring and recording animals, data collection, and data
analysis; providing temporary use of on-line
non-downloadable software for studying animals, data
collection, and data analysis; providing temporary use of
on-line non-downloadable software for monitoring and
recording animals, data collection, and data analysis in
animal husbandry; software as a service (SaaS) services,
namely, hosting software for use by others for monitoring
and recording the in vivo behavior and physiology of
laboratory animals, data collection, and data analysis;
software as a service (SaaS) services, namely, hosting
software for use by others for monitoring and recording
animals, data collection, and data analysis; software as a
service (SaaS) services, namely, hosting software for use by
others for studying animals, data collection, and data
analysis; software as a service (SaaS) services, namely,
hosting software for use by others for monitoring and
recording animals, data collection, and data analysis in
animal husbandry.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Indiana University Research and Technology Corporation (USA)
Sage Bionetworks (USA)
Inventor
Howell, Gareth
Carter, Gregory
Sasner, Michael
Rizzo, Stacey
Williams, Harriet
Lamb, Bruce
Territo, Paul
Oblak, Adrian
Logsdon, Ben
Mangravite, Lara
Graham, Leah
Abstract
The present disclosure provides a genetically modified mouse comprising a genomic nucleic acid encoding human APOE4, a genomic nucleic acid encoding mouse TREM2 modified to include a R47H substitution, and at least one genomic modification selected from the group consisting of: (a) a genomic nucleic acid encoding mouse ABCA7 modified to include an A 1541 G substitution; (b) a genomic nucleic acid encoding mouse APP modified to include G60IR, F606Y, and R609H substitutions; (c) a genomic nucleic acid encoding mouse PLCG2 modified to include a M28L substitution; (d) a genomic nucleic acid encoding mouse MTHFR modified to include a A262V substitution; (e) an inactivated Ceacaml allele; and (f) an inactivated II1rap allele. Methods of producing the genetically modified mouse and methods of using the genetically modified mouse are also provided.
The disclosure relates to methods that include obtaining cell-free deoxyribonucleic acid (cfDNA) from a sample of cerebrospinal fluid (CSF) from a subject having a brain tumor, profiling DNA methylation of the cfDNA using enzymatic methylation sequencing of the cfDNA to produce sequencing data and classifying the brain tumor of the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure provides, in some aspects, an immunodeficient NOD-Fcgr1null mouse that may be used to measure human IgG antibody pharmacokinetics and activity, produce human IgG antibodies, and model human disease treatment.
The invention, in some aspects, relates to methods and systems comprising long-read sequencing of DNA molecules for identifying target-specific genetic and epigenetic alterations in DNA sequence of interest.
Provided herein are methods comprising administering to a cancer patient an agent that modifies expression of a gene or function of a product encoded by the gene, wherein the gene is a human ortholog of a gene that maps to a mouse Chromosome 15 quantitative trait locus (QTL), for example, the human NCF4 gene.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
13.
METHODS AND SYSTEMS FOR NON-INVASIVE DETERMINATION OF ANIMAL MASS
Embodiments described herein relate to methods and systems for determining animal mass. The method can include receiving, by a processor of a computing device, video data representing observation of at least one animal, and executing, by the processor, a neural network architecture. Hie neural network architecture can be configured to receive an input video frame extracted from the video data, to generate an ellipse description of the at least one animal based upon the input video frame, the ellipse description being defined by predetermined ellipse parameters, and to estimate, based on the ellipse description, a mass value of the at least one animal.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical research services; Medical research in the field of endometriosis; Providing an on-line searchable database in the field of endometriosis for scientific research purposes; operating and maintaining a biorepository for medical and scientific research purposes; Providing medical and scientific research information Tissue bank services; Health care services, namely, providing a database in the field of endometriosis information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Providing a website featuring information in the field of the diagnosis and treatment of endometriosis; Providing medical information; Providing a web site featuring medical information; biorepository being tissue bank services; Providing information, news and commentary in the field of health and wellness relating to endometriosis; Receiving, preserving, storing, and disseminating human biological and tissue samples; Biobank services in the nature of providing access to human biological and tissue samples; biobank being human biological and tissue bank services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Promoting public awareness of endometriosis Education services, namely, providing information, lectures, educational training, and dissemination of materials therewith in the field of endometriosis
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Providing temporary use of non-downloadable cloud-based software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis; providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis; providing temporary use of non-downloadable cloud-based software for studying animals, data collection, and data analysis; providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis in animal husbandry; providing temporary use of on-line non-downloadable software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis; providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis; providing temporary use of on-line non-downloadable software for studying animals, data collection, and data analysis; providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis in animal husbandry; software as a service (SaaS) services, namely, hosting software for use by others for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis; software as a service (SaaS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis; software as a service (SaaS) services, namely, hosting software for use by others for studying animals, data collection, and data analysis; software as a service (SaaS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis in animal husbandry.
17.
METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH COMPRISING GDNF ADMINISTRATION
The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.
Provided herein are humanized mouse models and methods for determining whether administration of engineered immune cell therapies likely elicit cytokine release syndrome and/or determining the efficacy of an anti-disease therapy. Further, the models provided herein may be used to test the efficacy of different anti-CRS therapies.
This invention provides compositions, reagents, methods, and kits for isolating, amplifying, and sequencing extrachromosomal circular DNA (eccDNA or ecDNA), particularly eukaryotic eccDNA and ecDNA. The various embodiments of the invention provide methods for exponential amplification of eccDNA or ecDNA and subsequent nucleic acid sequencing to enable speedy diagnosis of a sample from a patient and genomic screening for disease states therein and identifying and providing treatment thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6867 - Replicase-based amplification, e.g. using Q-beta replicase
20.
Systems and Methods for Behavioral Analysis and AI-Enhanced Digital Biomarker Development
This disclosure describes a digitally enabled platform that includes animal (e.g., rodent) home cages with integrated cameras, cloud-based infrastructure, machine learning algorithms for generating digital biomarkers, and a user interface for collecting and visualizing continuous metrics for digital biomarkers in rats and mice. Metrics include movement, locomotion, wheel, food and water occupancy, loss of righting reflex, seizure, gait, rearing, and scratch. An array of sensors continuously monitors experimental conditions, minimizing the need for human intervention with the research subjects.
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
H04N 23/11 - Cameras or camera modules comprising electronic image sensorsControl thereof for generating image signals from different wavelengths for generating image signals from visible and infrared light wavelengths
The disclosure relates in some aspects to mammalian retinal pigment epithelial cells comprising an engineered activatable polynucleotide encoding a master regulatory transcription factor, compositions comprising the cells, methods of producing the cells, and methods of treatment using the cells. The disclosure also relates in some aspects to retinal grafts comprising induced pluripotent stem cell (iPSC)-derived retinal pigment epithelial cells, a proportion of which comprise an engineered polynucleotide comprising an inducible promoter operably linked to a neurogenin-2 coding sequence. Methods of using the retinal pigment epithelial cells and grafts for treating eye diseases are also provided herein.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biological preparations for use in industry and science; biological preparations for use in cell cultures, other than for medical or veterinary purposes; expression vectors and plasmids for scientific research; molecular biology research tools in the nature of biological and biochemical reagents, specifically vectors and plasmids; Reagents for scientific and research use; Cell culture reagents for scientific and research use; Reagents and cell markers for scientific and research purposes; Cell markers used as reagents for diagnostic, scientific, or research use Biological preparations for use in cell cultures for medical purposes; expression vectors and plasmids for clinical use; Reagents in the form of cell markers and molecule markers for medical purposes
The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.
An apparatus is provided for transporting laboratory animals that includes a container defining a first cavity and a second cavity, the container having an open top including a top nm surrounding a periphery of the open top. A divider is removably coupled to the container wherein the divider separates the first cavity and the second cavity and a cover is removably coupled to the top nm of the container. The cover includes a first portal that extends through the cover positioned, over the first cavity and a second portal that extends through the cover positioned over the second cavity. The cover also includes a first filtering mechanism and a second filtering mechanism. The base includes filtering mechanisms on the parallel long side walls. The apparatus further includes a first lid removably coupled to the first portal and a second lid removably coupled to the second portal.
Provided herein are devices and methods for providing anesthesia to a laboratory' animal using masks advantageously configured to secure the mask to the animal with reduced amounts or likelihood of slipping from the animal's nose during an experimental procedure while the animal is under anesthesia.
The human immune system is complex, and its related diseases are similarly complicated. Therefore, human diseases, such as cancers, are often difficult to characterize and treat effectively. Immunodeficient transgenic mice for use as humanized mouse models are provided. The humanized mouse models may be further engrafted with diseased tissues or cells (e.g., human cancer cells). Methods of using the humanized mouse models to assess disease progression, immune response, and efficacy of proposed therapeutic agents are also provided herein.
The present disclosure provides improved humanized IgG1 FCRN mouse models for use, for example, in estimating serum half-life of therapeutic proteins such as monoclonal antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
30.
METHODS AND COMPOSITIONS RELATING TO HUMANIZED STATHMIN2 MOUSE MODEL WITH DISRUPTED TDP-43 BINDING SITES
A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
31.
METHODS AND APPARATUS FOR IDENTIFYING ALTERNATIVE SPLICING EVENTS
Methods and apparatus for identifying alternative splicing events. The method comprises receiving a dataset of percent spliced in (PSI) values for each of a plurality of biological samples, wherein the plurality of biological samples includes a first population of samples having a first characteristic and a second population of samples having a second characteristic different from the first characteristic, fitting, to the dataset, a probabilistic model to identify clusters of samples in the dataset, calculating cluster characteristics for each of the clusters, filtering the clusters based, at least in part, on the cluster characteristics to identify a subset of clusters, each of which is associated with an alternative splicing event, and storing on the at least one storage device, information associated with the identified alternative splicing events.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
32.
METHODS AND COMPOSITIONS FOR SUPPRESSING AGING-ASSOCIATED CLONAL HEMATOPOIESIS
The present disclosure is directed to methods of treating clonal hematopoiesis in a subject thereof, comprising administering to the subject a mitochondria-targeted antioxidant in an amount effective to suppress clonal hematopoiesis in the subject, relative to an untreated control where the mitochondria-targeted antioxidant is a shortened form of the antioxidant ubiquinol with triphenylphosphonium.
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of non-downloadable cloud-based software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for studying animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis in animal husbandry;
Providing temporary use of on-line non-downloadable software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for studying animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis in animal husbandry;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for studying animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis in animal husbandry
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of non-downloadable cloud-based software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for studying animals, data collection, and data analysis;
Providing temporary use of non-downloadable cloud-based software for monitoring and recording animals, data collection, and data analysis in animal husbandry;
Providing temporary use of on-line non-downloadable software for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for studying animals, data collection, and data analysis;
Providing temporary use of on-line non-downloadable software for monitoring and recording animals, data collection, and data analysis in animal husbandry;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording the in vivo behavior and physiology of laboratory animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for studying animals, data collection, and data analysis;
Software as a service (SAAS) services, namely, hosting software for use by others for monitoring and recording animals, data collection, and data analysis in animal husbandry
35.
DEVICES AND METHODS FOR CREATING TRANSCELLULAR PORES
Disclosed herein is a biochip with a plurality of endothelial cells (e.g., Schlemm's canal cells) having a plurality of pores (e.g., transcellular pores) and methods of making and using the same.
The present disclosure provides improved humanized IgG1 FCRN mouse models for use, for example, in estimating serum half-life of therapeutic proteins such as monoclonal antibodies.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This disclosure provides methods for treating obesity in a subject with an agent that inhibits Na-K-Cl co-transporter 1 (NKCC1) and/or an agent that increases K-Cl co- transporter 2 (KCC2); and a pharmaceutical composition to treat same containing each or both of these agents.
Systems and methods described herein provide techniques for determining a visual frailty score by processing video data of a subject. Various features maybe used to determine the visual frailty score, including but not limited to, spinal mobility features, gait measurements, behavior features, and body composition data. The various features may be extracted from the video data using different techniques. The various features may be processed using one or more machine learning models to determine the visual frailty score.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical testing services; Medical testing for diagnostic or treatment purposes; Genetic testing for medical purposes; Medical testing for diagnostic or treatment purposes in the field of oncology
The invention relates, in part, to methods of assessing small deletion signatures to determine treatments for cancers and to determine a prognosis for a subject having a cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
42.
GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF
Indiana University Research and Technology Corporation (USA)
Inventor
Howell, Gareth
Sasner, Michael
Carter, Gregory
Lamb, Bruce
Abstract
Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.
The disclosure relates to compositions and methods for treating cocaine addiction in a subject in need thereof utilizing a therapeutically effective amount of the hydrophobic 5-hydroxytryptamine receptor 1 D-specific agonist: (S)-3,4-dihydro-1-[2;[4-(4-methoxyphenyl)-1-piperazinyl]ethyl]-N-methyl-1 H-2-benzopyran-6-carboxamide, capable of crossing the blood-brain barrier. Further, the agonist alleviates volitional cocaine-taking behavior, facilitates recovery for cocaine addiction and prevents relapse into cocaine addiction.
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The Trustees of the University of Pennsylvania (USA)
Inventor
Kumar, Vivek
Pack, Allan I.
Geuther, Brian
George, Joshy
Chen, Mandy
Abstract
Systems and methods described herein provide techniques for determining sleep state data by processing video data of a subject. Systems and methods may determine a plurality of features from the video data, and may determine sleep state data for the subject using the plurality of features. In some embodiments, the sleep state data may be based on frequency domain features and/or time domain features corresponding to the plurality of features.
Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
46.
SYSTEMS AND METHODS FOR BEHAVIORAL ANALYSIS AND AI-ENHANCED DIGITAL BIOMARKED DEVELOPMENT
This disclosure describes a digitally enabled platform that includes animal (e.g, rodent) home cages with integrated cameras, cloud-based infrastructure, machine learning algorithms for generating digital biomarkers, and a user interface for collecting and visualizing continuous metrics for digital biomarkers in rats and mice. Metrics include movement, locomotion, wheel, food and water occupancy, loss of righting reflex, seizure, gait, rearing, and scratch. An array of sensors continuously monitors experimental conditions, minimizing the need for human intervention with the research subjects.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 20/52 - Surveillance or monitoring of activities, e.g. for recognising suspicious objects
47.
GENE MUTATIONS ASSOCIATED WITH TANDEM DUPLICATOR PHENOTYPE
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Example microscopy caps include a base portion configured to fit over an outer lens of a microscope objective and a. top portion that includes a liquid repository to retain an immersion liquid and a lens aperture to align with the outer lens of the microscope objective when the base portion is fit over the outer lens of the microscope objective.
The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
Systems and methods described herein provide techniques for automated phenotyping. The systems and methods, in some embodiments, processes video data, identifies body parts, extracts features on a frame-level, and determines subject behavior captured in the video data. The systems and methods may use one or more machine learning models.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
G06V 20/40 - ScenesScene-specific elements in video content
G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
G06V 40/10 - Human or animal bodies, e.g. vehicle occupants or pedestriansBody parts, e.g. hands
G06V 40/20 - Movements or behaviour, e.g. gesture recognition
Provided herein, in some aspects, is a multiplex RNA targeting system that enables live cell imaging and/or modification of multiple RNA targets. Specifically, the disclosure provides a method of live cell imaging of ribonucleic acid (RNA), or targeting RNA in a live cell, comprising: (a) delivering to a cell an RNA-editing complex that comprises a catalytically inactive Cas13 (dCas13) nuclease, a Cas 13 guide RNA (gRNA) comprising an RNA aptamer sequence, and a detectable molecule linked to an RNA-binding domain (RBD), or an RNA effector molecule linked to an RBD sequence that specifically binds to the RNA aptamer sequence; and (b) imaging the detectable molecule or RNA aptamer and RBD binding.
ARIZONA BOARD OF REGENTS on behalf of ARIZONA STATE UNIVERSITY (USA)
CONNECTICUT CHILDREN'S MEDICAL CENTER (USA)
THE JACKSON LABORATORY (USA)
Inventor
Cheng, Albert
Lau, Ching
Jillette, Nathaniel
Zhu, Jacqueline Jufen
Abstract
The present disclosure provides compositions and methods related to nucleic acid sensors. In particular, the present disclosure provides nucleic acids molecules that target transcripts of a gene or chromosomal fusion and activate a downstream event, including the production of a detectable signal and/or exert a therapeutic function.
Provided herein are, inter alia, compositions and methods for demethylating and methylating a target DNA sequences in a mammalian cell. The compositions and methods are, inter alia, useful for modulating the expression of a target gene, or to create a gene regulatory network.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
Provided herein, in some embodiments, are methods for modulating expression and/or activity of transient receptor potential cation channel subfamily C, member 3 (TRPC3), as well as methods of treating Alzheimer's disease.
A01K 67/027 - New or modified breeds of vertebrates
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure provides, in some aspects, humanized immunodeficient mouse models that support long-term engraftment and function of human T cells, natural killer cells, and myeloid cells, without the need for conditioning.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Cells for scientific and research use; Cells for scientific, laboratory or medical research; Cells containing all intended transgenes for scientific, laboratory or medical research
60.
METHODS AND COMPOSITIONS FOR INHIBITING CLONAL HEMATOPOIESIS
Clonal hematopoiesis is an age-related condition caused by somatic mutations that give a hematopoietic stem cell a clonal selective advantage. While clonal hematopoiesis is a benign condition, individuals affected by it have an increased risk of developing blood cancers, such as acute myeloid leukemia (AML). The present disclosure provides, in some aspects, methods for inhibiting clonal hematopoiesis using a senolytic agent to target senescence of bone marrow stromal cells.
The present disclosure provides immunodeficient mouse models that comprise a nucleic acid encoding a human or humanized amyloid precursor protein (APP) and, in some models, further comprise a nucleic acid encoding a mutated human presenilin 1 protein (PSEN1). These mouse models are useful, for example, for Alzheimer's disease studies.
A01K 67/027 - New or modified breeds of vertebrates
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
62.
PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS
Provided herein, in some embodiments, are novel methods for predicting response to a platinum-based chemotherapeutic agent in triple negative breast cancer and ovarian carcinoma.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Systems and methods described herein provide techniques for analyzing gait and posture of a subject with respect to control data. The systems and methods, in some embodiments, processes video data, identifies keypoints representing body parts, determines metrics data at a stride level, and compares the metrics data to control data.
Provided herein are immnunodeficient mouse models engrafted with cells comprising a pathogen entry moiety, for example, for assessing pathogenic infection. The pathogen may be a virus, such as a respiratory virus.
Provided herein are antimicrobial biosensors for skin for treating Staphylococcus aureus Type I, Type II, Type III, and/or Type IV infection. In some embodiments, the antimicrobial biosensors are expressed in Staphylococcus epidermidis cells.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Provided herein are humanized mouse models generated using T cell-negative fractions or peripheral blood mononuclear cells obtained from T cell-negative fractions, and methods of using the mouse models to assess the efficacy and/or side effects of a therapeutic agent. Immune cell therapies require a large number of cells. Most commonly, the cells are collected using a process referred to as apheresis. Apheresis collection of the mononuclear cell (MNC) layer has been shown to be a safe and efficient method of collecting the large number of T cells.
Systems and methods for continuous monitoring of the behavior of animals, such as small rodents, are provided. Monitoring can include video, audio, and other sensor modalities. In one embodiment, the system can include cameras, arena design, environmental sensors, and ultrasonic sensors. The system uniquely provides a continuous long-term monitoring system suitable for mouse behavioral study. Further provided is a neural network based tracker configured for use with video data acquired by the monitoring system. 3 different neural network architectures have been tested to determine their performance on genetically diverse mice under varying environmental conditions. It has been observed that that an encoder-decoder segmentation neural network achieves high accuracy and speed with minimal training data. This general purpose neural network tracker can be easily extended to other experimental paradigms and even to other animals through transfer learning, thus forming a robust, generalizable solution for bio-behavioral research.
G06F 18/21 - Design or setup of recognition systems or techniquesExtraction of features in feature spaceBlind source separation
G06F 18/2413 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
G06F 18/28 - Determining representative reference patterns, e.g. by averaging or distortingGenerating dictionaries
G06N 3/04 - Architecture, e.g. interconnection topology
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/772 - Determining representative reference patterns, e.g. averaging or distorting patternsGenerating dictionaries
Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
69.
THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING
Provided herein are methods of inhibiting type 1 receptor and/or type 2 receptor signaling in subjects, optionally subjects with diseases associated with myostatin, type 1 receptor, and/or type 2 receptor signaling, or muscle loss and/or bone deterioration. Also provided are compositions for inhibition of type 1 receptor and/or type 2 receptor signaling.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
Provided herein are chemically modified antisense oligonucleotides that bind to sequences on mRNAs encoding the splicing factor TKA2β, associated with cancer.
Systems and methods for generating a graph describing cross-species relationships between gene variants associated with two or more species are provided herein. The techniques include obtaining data generated by first genomic studies of a first species and second genomic studies of a second species, the data including a plurality of datasets including two or more data formats. A subset of the data is stored in a cache and then transformed into a database having a uniform data format, the database describing graph objects and connections between the graph objects. The database is built by iteratively caching and transforming subsets of the data, each transformed subset being stored in non-transient computer-readable memory. The graph is then generated using the database.
Improved mounts and other elements are provided to facilitate alignment of multi- tube sample holders with multi-stream cell- and/or other particle-sorting apparatus. These elements are able to adjust the location of a tube holder relative to the particle sorting apparatus in several degrees of freedom, allowing the alignment of the tubes to the sorter to be easily and accurately adjusted, thereby improving sorted sample capture and reducing technician effort and. time. Additionally, these elements can include a laser or laser mount to facilitate visualization of the streams relative to the tubes, thereby facilitating adjustment of the relative location of the tubes. Such a laser mount can be adjustable to control the location and orientation of a laser mounted thereto relative to the tubes and/or particle-bearing droplet streams, facilitating visualization of the streams.
The present disclosure relates to genetically modified non-obese diabetic (NOD) mice deficient in murine class I MHC molecules, class II molecules, or both class I and class II MHC molecules. The MHC knockout transgenic mice provided herein are useful, for example, for developing therapies for diabetes.
An arrangement for reducing intraocular pressure includes a pulse signal source, a probe coupling, and at least one electrode. The probe coupling is configured to be supported on a portion of a living eye. The electrodes are supported on the probe coupling. The electrodes are operably coupled to receive a pulse signal from the pulse signal source.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
Provided herein, in some embodiments, are methods, compositions, and systems for identifying alternatively spliced tumor-specific exon inclusion and exclusion events that can be used for survival prognosis.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
76.
TRANSGENIC MOUSE MODELS OF HUMAN ADAPTIVE AND INNATE IMMUNITY AND METHODS OF USE
Provided herein are humanized immunodeficient mouse comprising human myeloid cells and human lymphoid cells, wherein the human lymphoid cells comprise human B cells that produce circulating immunoglobulin (Ig), for example, physiological levels of human IgG, and wherein the mouse expresses a detectable level of human FLT3L protein and does not express a detectable level of mouse FLT3 protein.
An anchoring device may include a body including a cavity configured to receive a data logger disposed therein. An anchoring device may include an anchoring portion attached to the body. An anchoring device may include one or more through holes formed in the anchoring portion, where the one or more through holes are configured to accept a suture passing therethrough to attach the anchoring device to tissue of a subject.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61N 1/375 - Constructional arrangements, e.g. casings
Systems and methods described herein provide techniques for detecting subject behavior by processing video data using one or more trained models configured to detect subject behavior. The described system processes sets of frames from the video data using different trained models. The system further processes different orientations of the sets of frames. The various outputs from the different trained models and from processing the different orientations of the sets of frames may be combined to then make a final determination as to whether the subject is exhibiting a particular behavior during a particular frame.
Disclosed are bispecific molecules combining ACE2 with an anti-CD3 antibody and engineered T cells expressing chimeric antigen receptors that bind to SARS-CoV-2 spike protein, as well as related compositions and methods. The methods and compositions provided can be used for treating early-stage and/or late-stage SARS-CoV-2 infections, independent of the SARS-CoV-2 variant.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
TTNTTN gene in a cell or tissue in an animal or human wherein at least one allele of the gene carries a mutation that results in a truncated Titin protein product. Therapeutic treatments, pharmaceutical compositions and methods of treatment utilizing such pharmaceutical compositions are also provided.
The present disclosure provides immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG™) mouse models that comprise an inactivated mouse Flt3 allele and, in some models, additional genetic modifications. These mouse models useful, for example, for superior engraftment of diverse hematopoietic lineages and for immune-oncology, immunology and infectious disease studies.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Fcgr1nullnull mouse that may be used to measure human IgG antibody pharmacokinetics and activity, produce human IgG antibodies, and model human disease treatment.
The invention described herein provides compositions and reagents for integrating large sequences (e.g., 150 bp or more) into a selected target DNA sequence via prime editing.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable software for genetic
assessment and identification of cancer, diseases, health
status and metrics, and gene mutations for scientific,
medical, diagnostic, treatment, and research purposes;
providing online non-downloadable software used for the
sequencing and analyses of genomic data, transcriptomic
data, proteomic data, DNA, RNA, and protein; providing
online non-downloadable software used to predict, integrate
and create data models; providing information about genomic
sequences for scientific research, namely, for tracking,
matching, searching, testing, aggregating, researching, and
evaluating health status, and diagnosing diseases and gene
mutations from an online computer database; design and
development of databases for tracking, matching, searching,
testing, aggregating, researching, and evaluating health
status and for diagnosing diseases and gene mutations;
predictive digital computer modeling for analyzing and
visualizing genomic data, and evaluating health status and
diagnosing diseases, disorders, and syndromes; providing
online non-downloadable software for collecting, analyzing,
reporting, and tracking data and information in the fields
of genetics, genomics, biology, biochemistry.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Live laboratory mice and other live laboratory animals. Medical research services; biomedical research services;
structural and functional analysis of genomes. Mice breeding services.
The present disclosure provides methods and compositions for high frequency, targeted mammalian transgenesis using, for example, a two-step, two-stage process that enables integrating anywhere in the mammalian genome large pieces of nucleic acid in single generation.
The present disclosure provides wild-derived mouse models that comprise a nucleic acid encoding a human amyloid precursor protein (APP), a nucleic acid encoding a mutated human presenilin (1) protein (PSEN1), and in some embodiments, a human apolipoprotein E (APOE), or human amyloid beta and human tau. These mouse models are useful, for example, for Alzheimer's disease studies.
The present disclosure provides an immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG™) mouse models that comprise an inactivated mouse Flt3 allele, a nucleic acid encoding human interleukin 3 (IL3), a nucleic acid encoding human granulocyte/macrophage-stimulating factor (GM-CSF), a nucleic acid encoding human stem cell factor (SCF), and a HLA-A2/H2-D/B2M transgene encoding (i) a human B2-microglubulin (B2M) covalently linked to MHC class 1, alpha 1, and alpha2 binding domains of a human HLA-A2.1 gene and (ii) alpha3 cytoplasmic and transmembrane domains of murine H2-db.
The present disclosure provides a transgenic, immunocompromised mouse engineered to express a human angiotensin converting enzyme 2 (huACE2) sequence. The huACE2 sequence may be operably linked to a human keratin 18 (hKRT18) promoter or the endogenous mouse angiotensin converting enzyme 2 (mACE2) promoter. Transgenic immunocompromised mice of the present disclosure may be utilized in methods of evaluating a test agent for reducing or preventing SARS-CoV-2 infection.
Disclosed are bispecific T cell engager molecules combining ACE2 with anti-CD3 and engineered SARS-CoV-2 spike protein- specific chimeric antigen receptors, as well as related compositions and methods. The methods and compositions provided can be used for treating early-stage and/or late-stage SARS-CoV-2 infections, independent of the SARS- CoV-2 variant.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The invention, in some aspects, relates to methods and systems comprising long-read sequencing of DNA molecules for identifying target-specific genetic and epigenetic alterations in DNA sequence of interest.
The human immune system is complex, and its related diseases are similarly complicated. Therefore, human diseases, such as cancers, are often difficult to characterize and treat effectively. Immunodeficient transgenic mice for use as humanized mouse models are provided. The humanized mouse models may be further engrafted with diseased tissues or cells (e.g., human cancer cells). Methods of using the humanized mouse models to assess disease progression, immune response, and efficacy of proposed therapeutic agents are also provided herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceutical preparations for the prevention and treatment of ocular disorders, ocular conditions, ocular diseases, and ocular aging; nutraceutical preparations, namely, ophthalmic preparations for prevention and treatment of ocular disorders, ocular conditions, ocular diseases, and ocular aging; nutraceutical preparations for the prevention and treatment of glaucoma; nutraceutical preparations, namely, ophthalmic preparations for the prevention and treatment of glaucoma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceutical preparations for the prevention and treatment of ocular disorders, ocular conditions, ocular diseases, and ocular aging; nutraceutical preparations, namely, ophthalmic preparations for prevention and treatment of ocular disorders, ocular conditions, ocular diseases, and ocular aging; nutraceutical preparations for the prevention and treatment of glaucoma; nutraceutical preparations, namely, ophthalmic preparations for the prevention and treatment of glaucoma
99.
METHODS AND COMPOSITIONS RELATING TO HUMANIZED STATHMIN2 MOUSE MODEL WITH DISRUPTED TDP-43 BINDING SITES
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
100.
METHODS AND COMPOSITIONS FOR SUPPRESSING AGING-ASSOCIATED CLONAL HEMATOPOIESIS
The present disclosure is directed to methods of treating clonal hematopoiesis in a subject thereof, comprising administering to the subject a mitochondria-targeted antioxidant in an amount effective to suppress clonal hematopoiesis in the subject, relative to an untreated control where the mitochondria-targeted antioxidant is a shortened form of the antioxidant ubiquinol with triphenylphosphonium.
